Zhou Xu, Wu Qingni, Wang Yanping, Ren Qing, Zhu Weifeng, Yao Ziqian, Chen Jianrong
Evidence-Based Medicine Research Center, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, China.
Department of Orthopedics and Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Evid Based Complement Alternat Med. 2020 Oct 28;2020:6128673. doi: 10.1155/2020/6128673. eCollection 2020.
This systematic review aims to investigate the efficacy and safety of moxibustion for chronic kidney disease (CKD).
Nine databases were searched to identify relevant evidence up to March 8, 2020. Randomized controlled trials (RCTs) that tested moxibustion + basic treatments versus basic treatments alone for patients with CKD and reported, at least, one of the outcomes of interest were included. In the meta-analyses, the mean differences (MDs) and 95% confidence intervals (CIs) were used to measure the effect size.
Twenty-three RCTs ( = 1571) with a moderate to high risk of bias were included. The pooled estimates showed that compared with the controls, patients after moxibustion had a significant reduction in serum creatinine (MD -17.34 mol/L, 95% CI -28.44 to -6.23; = 87%), 24-hour urine protein excretion (MD -0.75 g/h, 95% CI -1.07 to -0.42; = 84%), and blood urea nitrogen (MD -0.63 mmol/L, 95% CI -1.09 to -0.18; = 37%) and a significant improvement in the quality of life (MD 10.18, 95% CI 3.67 to 16.69; = 57%). Moxibustion did not show a significant effect on the estimated glomerular filtration rate (eGFR), creatinine clearance, or hemoglobin. The subgroup analyses showed that a longer course of moxibustion (>8 weeks) and indirect moxibustion had a greater effect on reducing serum creatinine. The effect of moxibustion on blood urea nitrogen changed to be nonsignificant after excluding RCTs with a high risk of bias (MD -0.96 mmol/L, 95% CI -2.96 to 1.03). Only one adverse event of burn was reported.
This systematic review suggests that, as an adjuvant therapy, moxibustion may improve serum creatinine, urinary protein excretion, blood urea nitrogen, and quality of life in patients with CKD. Moxibustion may not have effects on eGFR, creatinine clearance, or hemoglobin. The quality of evidence is weakened by the limitations of risk of bias, heterogeneity, and imprecision.
本系统评价旨在研究艾灸治疗慢性肾脏病(CKD)的疗效和安全性。
检索9个数据库以识别截至2020年3月8日的相关证据。纳入对CKD患者进行艾灸+基础治疗与单纯基础治疗比较的随机对照试验(RCT),且至少报告一项感兴趣的结局。在荟萃分析中,采用平均差(MD)和95%置信区间(CI)来衡量效应大小。
纳入23项偏倚风险为中度至高风险的RCT(n = 1571)。汇总估计显示,与对照组相比,艾灸后患者的血清肌酐显著降低(MD -17.34μmol/L,95%CI -28.44至-6.23;I² = 87%),24小时尿蛋白排泄量显著降低(MD -0.75g/h,95%CI -1.07至-0.42;I² = 84%),血尿素氮显著降低(MD -0.63mmol/L,95%CI -1.09至-0.18;I² = 37%),生活质量显著改善(MD 10.18,95%CI 3.67至16.69;I² = 57%)。艾灸对估计肾小球滤过率(eGFR)、肌酐清除率或血红蛋白无显著影响。亚组分析显示,艾灸疗程较长(>8周)和间接艾灸对降低血清肌酐的效果更大。在排除偏倚风险高的RCT后,艾灸对血尿素氮的影响变为无显著意义(MD -0.96mmol/L,95%CI -2.96至1.03)。仅报告1例烧伤不良事件。
本系统评价表明,作为一种辅助治疗,艾灸可能改善CKD患者的血清肌酐、尿蛋白排泄、血尿素氮和生活质量。艾灸可能对eGFR、肌酐清除率或血红蛋白无影响。证据质量因偏倚风险、异质性和不精确性的局限性而减弱。